Charlottesville, VA – July 20, 2022 – Adial Pharmaceuticals, Inc. (NASDAQ:
ADIL; ADILW) (“Adial” or the “Company”), a clinical-stage biopharmaceutical
company focused on developing
The U.S. Stock Market has had a rough 2022 so far and the SPDR Dow Jones Industrial Average ETF Trust (NYSEARCA: DIA) has been no exception to that. Since the start of the calendar year, the index has lost close to 6,000 points as inflation continues to rise and consumer spending falls.